Whalesbook
Toh bhai, MSN Pharmaceuticals ne Astellas Pharma ke saath final deal kar li hai U.S. mein mirabegron drug, jise hum Myrbetriq ke naam se jaante hain, uske generic version ko market karne ke liye. Iske liye MSN ne upfront $75 Million bhi de diye hain. Is deal ne formulation aur 'food-effect' details par jo patent disputes the, woh bhi solve kar diye hain. Iska matlab MSN apna generic version sell karna jari rakh sakta hai. Astellas ko bhi ek accha upfront payment mila hai, aur drug ke patent expiry ke paas hone par per-unit licensing fees bhi milengi. Mazedaar baat yeh hai ki Astellas ki Indian drugmakers ke liye yeh teesri aisi settlement hai, pehle Lupin aur Zydus se bhi aisi deals ho chuki hain.
Ab main point yeh hai ki MSN ki settlement terms shayad Lupin aur Zydus ki terms se zyada achhi ho sakti hain. Pehle Lupin ne roughly $90 Million diye the (jismein $75 Million upfront the), aur Zydus ne toh $120 Million ka commitment diya tha. Dono ne September 2027 tak licensing fees par bhi haan bhar di thi. Jaise hi yeh khabar market mein faili, Zydus Lifesciences ke shares 2.37% aur Lupin ke shares 2.03% BSE par gir gaye. Investors ka reason yeh hai ki MSN agar kam cost par utrega toh competition jaldi badhega, jisse Lupin aur Zydus ke U.S. mirabegron market (jo lagbhag $1 Billion ka hai) mein profits kam ho jayenge. Astellas ne kaha hai ki iska financial impact unke fiscal year 2027 guidance mein dikhega.
Lupin aur Zydus dono ne hi Astellas ke saath mirabegron generic ko lekar kafi patent litigation face ki thi. Shuru mein courts ne inke favour mein decision diya tha, lekin phir appeals court ne kuch sawal uthaye. March 2026 mein ek Delaware court ne finally Astellas ke patent ko valid bataya. Yahi wajah thi ki February 2026 mein Lupin ne $90 Million aur Zydus ne $120 Million ki deals ki thi, taaki woh sales secure kar sakein aur kuch time ke liye limited competition ka fayda utha sakein. Lekin ab MSN ki entry, aur woh bhi potentially behtar terms ke saath, is limited competition wale period ko chhota kar sakti hai.
Lupin ki market cap around ₹1.06 Trillion hai (P/E 22.65x-24.2x), aur Zydus Lifesciences ki roughly ₹95,000 Crore INR hai (P/E 19.00x-20.06x). Waise toh Indian pharma sector U.S. market mein pricing pressures ke chalte slow growth dekh raha hai. Lupin ko mirabegron aur tolvaptan se U.S. mein acchi growth ki ummeed thi. U.S. Overactive Bladder (OAB) market jo $1.078 Billion ka tha 2024 mein, uski growth bhi moderate hi rehne ka anuman hai. Astellas Pharma ka is market mein kafi bada share hai.
Analyst firm UBS ne March 25, 2026 ko Lupin aur Zydus dono ko 'Sell' rating di thi. Unka reason tha ki companies sirf one-time patent settlement income par depend kar rahi hain aur unke paas GLP-1 drugs jaise competitive areas mein growth ke liye zyaada diverse options nahi hain. Achha, settlements ne legal risks toh clear kar diye, lekin MSN ki potentially better deal limited competition ke faayde ko kam kar sakti hai aur margins par pressure daal sakti hai. Settlement se pehle, Zydus ki quarterly mirabegron sales $35 Million aur Lupin ki $25–30 Million tak thi. U.S. mein generic price erosion badhne, expenses badhne aur compliance issues ki wajah se in deals se hone wala profit expect se pehle kam ho sakta hai. Innovator patents ko challenge karna toh risk ka kaam hai hi.
Toh ab MSN ki yeh nayi settlement structure U.S. generic mirabegron market mein competition ko aur badha degi, jisse Lupin aur Zydus ke liye recent deals se hone wale short-term fayde kam ho sakte hain. Settlements ne litigation risks ko manage karne aur market access ko maintain karne mein help ki thi, lekin unki long-term value tabhi rahegi jab Lupin aur Zydus apne products aur revenue streams ko properly diversify karenge. Analysts warn kar rahe hain ki sirf in single-product settlements par depend karna koi long-term strategy nahi hai, especially jab U.S. mein price pressures kam nahi ho rahe hain. Lupin aur Zydus ko apne OAB treatments ko carefully manage karna hoga aur saath hi naye growth areas bhi explore karne honge.